23

Knowledge Library

BILIARY TRACT CANCER

IL-4 modulate the tumor microenvironment and response to cancer therapies
http://cancerres.aacrjournals.org/content/76/14_Supplement/1454.short

Targeting IL4/IL4R for the treatment of epithelial cancer metastasis
https://www.ncbi.nlm.nih.gov/pubmed/26385103

Potent in vitro and in vivo antitumor activity of interleukin-4-conjugated Pseudomonas exotoxin against human biliary tract carcinoma
http://www.ncbi.nlm.nih.gov/pubmed/18798553

BLADDER CANCER

Interleukin-4 receptor targeted immunotherapy of human bladder cancer in animal models
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4292317/

BRAIN CANCER

IL-13 receptors as possible therapeutic targets in diffuse intrinsic pontine glioma
https://www.ncbi.nlm.nih.gov/pubmed/29621254

Convection-enhanced delivery in glioblastoma: a review of preclinical and clinical studies
https://www.ncbi.nlm.nih.gov/pubmed/27035164

Expression and structure of interleukin 4 receptors in primary meningeal tumors
http://www.ncbi.nlm.nih.gov/pubmed/15830341

Expression and structure of interleukin 4 receptor (IL-4R) complex in human invasive pituitary adenomas
http://www.ncbi.nlm.nih.gov/pubmed/17398005

Cytotoxins directed at interleukin-4 receptors as therapy for human brain tumors.
http://www.ncbi.nlm.nih.gov/pubmed/11217365

Local convection enhanced delivery of IL4-Pseudomonas exotoxin (NBI-3001) for treatment of patients with recurrent malignant glioma
http://www.ncbi.nlm.nih.gov/pubmed/14531567

Convection-enhanced Delivery of Free Gadolinium with the Experimental Chemotherapeutic Agent PRX321
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3150410/

Complete regression of established human glioblastoma tumor xenograft by interleukin-4 toxin therapy
http://www.ncbi.nlm.nih.gov/pubmed/9721874

In situ expression of interleukin-4 (IL-4) receptors in human brain tumors and cytotoxicity of a recombinant IL-4 cytotoxin in primary glioblastoma cell cultures
http://www.ncbi.nlm.nih.gov/pubmed/11719427

IL-4 receptors on human medulloblastoma tumours serve as a sensitive target for a circular permuted IL-4-Pseudomonas exotoxin fusion protein
http://www.ncbi.nlm.nih.gov/pubmed/11870521

Interleukin-4-Pseudomonas exotoxin chimeric fusion protein for malignant
glioma therapy
http://www.ncbi.nlm.nih.gov/pubmed/14649882

Convection-Enhanced Drug Delivery of Interleukin-4 Pseudomonas Exotoxin (PRX321): Increased Distribution and Magnetic Resonance Monitoring
http://www.ncbi.nlm.nih.gov/pubmed/19478131

Toxicologic Pathology of Cytokines, Cytokine Receptors, and Other Recombinant Human Proteins – Development of a Recombinant Interleukin-4-Pseudomonas Exotoxin for Therapy of Glioblastoma
http://www.ncbi.nlm.nih.gov/pubmed/10367674

Human neurological cancer cells express interleukin-4 (IL-4) receptors which are targets for the toxic effects of IL4-Pseudomonas exotoxin chimeric protein
http://www.ncbi.nlm.nih.gov/pubmed/8056454

Preclinical development of a recombinant toxin containing circularly permuted interleukin 4 and truncated Pseudomonas exotoxin for therapy of malignant astrocytoma
http://www.ncbi.nlm.nih.gov/pubmed/8971168

A Review of Studies on Targeting Interleukin 4 Receptor for Central Nervous System Malignancy
http://www.ncbi.nlm.nih.gov/pubmed/19689300

Long term survival in a patient with recurrent malignant glioma treated with intratumoral infusion of an IL4-targeted toxin (NBI-3001)
http://www.ncbi.nlm.nih.gov/pubmed/15015787

Clinical Studies with Targeted Toxins in Malignant Glioma
http://www.ncbi.nlm.nih.gov/pubmed/18473963

Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma
http://www.ncbi.nlm.nih.gov/pubmed/10873064

The IL-4 and IL-13 pseudomonas exotoxins: new hope for brain tumor therapy
http://www.ncbi.nlm.nih.gov/pubmed/16709016

Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin
(NBI-3001) in patients with recurrent malignant glioma
http://www.ncbi.nlm.nih.gov/pubmed/12952293

A mathematical model of the impact of infused targeted cytotoxic agents on brain tumours: implications for detection, design and delivery
http://www.ncbi.nlm.nih.gov/pubmed/12427253

BREAST CANCER

Elevated Interleukin-13 Receptor Alpha 1 Expression in Tumor Cells Is Associated with Poor Prognosis in Patients with Invasive Breast Cancer
https://www.ncbi.nlm.nih.gov/pubmed/28634667

IL4 Primes the Dynamics of Breast Cancer Progression via DUSP4 Inhibition
https://www.ncbi.nlm.nih.gov/pubmed/28400477

IL-4 modulate the tumor microenvironment and response to cancer therapies
http://cancerres.aacrjournals.org/content/76/14_Supplement/1454.short

Targeting IL4/IL4R for the treatment of epithelial cancer metastasis
http://www.ncbi.nlm.nih.gov/pubmed/26385103

Lessons from immunology: IL4R directly promotes mammary tumor metastasis
http://www.ncbi.nlm.nih.gov/pubmed/25941616

IL4 receptor α mediates enhanced glucose and glutamine metabolism to support breast cancer growth
http://www.ncbi.nlm.nih.gov/pubmed/25746764

IL4 receptor ILR4α regulates metastatic colonization by mammary tumors through multiple signaling pathways
http://www.ncbi.nlm.nih.gov/pubmed/24947041

Effect of interleukin (IL)-4 cytotoxin on breast tumor growth after in vivo gene transfer of IL-4 receptor alpha chain
http://www.ncbi.nlm.nih.gov/pubmed/12738741

Human Breast Carcinoma Cells Express Type II IL-4 Receptors and Are Sensitive to Antitumor Activity of a Chimeric IL-4-Pseudomonas Exotoxin Fusion Protein in
vitro and in vivo                  
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1949945/

CANCER STEM CELLS

Interleukin-4 induces a CD44high /CD49bhigh PC3 subpopulation with tumor-initiating characteristics
https://www.ncbi.nlm.nih.gov/pubmed/29236307

The immunosuppressive cytokine interleukin-4 increases the clonogenic potential of prostate stem-like cells by activation of STAT6 signaling
https://www.ncbi.nlm.nih.gov/pubmed/28553931

IL-13/STAT6 signaling plays a critical role in the epithelial-mesenchymal transition of colorectal cancer cells
https://www.ncbi.nlm.nih.gov/pubmed/27533463

Targeting of IL-4 and IL-13 receptors for cancer therapy
http://www.ncbi.nlm.nih.gov/pubmed/26088753

Crucial role of interleukin-4 in the survival of colon cancer stem cells
http://www.ncbi.nlm.nih.gov/pubmed/18519657

Survivin Is Regulated by Interleukin-4 in Colon Cancer Stem Cells
http://www.ncbi.nlm.nih.gov/pubmed/20506498

Colon Cancer Stem Cells Dictate Tumor Growth and Resist Cell Death by Production of Interleukin-4
http://www.ncbi.nlm.nih.gov/pubmed/18371377

IL-4-mediated drug resistance in colon cancer stem cells
http://www.ncbi.nlm.nih.gov/pubmed/18235245

Cancer-initiating cells from colorectal cancer patients escape from T cell-mediated immunosurveillance in vitro through membrane-bound IL-4
http://www.ncbi.nlm.nih.gov/pubmed/24277698

COLON AND COLORECTAL CANCER

Interleukin-4 and interleukin-13 increase NADPH oxidase 1-related proliferation of human colon cancer cells
https://www.ncbi.nlm.nih.gov/pubmed/28498822

IL-13/STAT6 signaling plays a critical role in the epithelial-mesenchymal transition of colorectal cancer cells
https://www.ncbi.nlm.nih.gov/pubmed/27533463

Expression of interleukin-4 and interleukin-13 and their receptors in colorectal cancer
http://www.ncbi.nlm.nih.gov/pubmed/22441356

Epithelial interleukin-4 receptor expression promotes colon tumor growth
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2878360/

HEAD AND NECK CANCER

Structure, Function, and Targeting of Interleukin 4 Receptors on Human Head and Neck Cancer Cells
http://www.ncbi.nlm.nih.gov/pubmed/10850446

Interleukin 4 Receptor-directed Cytotoxin Therapy for Human Head and Neck Squamous Cell Carcinoma in Animal Models
http://www.ncbi.nlm.nih.gov/pubmed/11801570

Head and neck cancers, but not benign lesions, express interleukin-4 receptors in situ
http://www.ncbi.nlm.nih.gov/pubmed/9458290

IL-2 Superkines

IL-4 SUPERKINES

IL-4 modulate the tumor microenvironment and response to cancer therapies
http://cancerres.aacrjournals.org/content/76/14_Supplement/1454.short

Targeting IL4/IL4R for the treatment of epithelial cancer metastasis
http://www.ncbi.nlm.nih.gov/pubmed/26385103

Redirecting cell-type specific cytokine responses with engineered interleukin-4 superkines
http://www.ncbi.nlm.nih.gov/pubmed/23103943

Immunology: Evolving superkines for selectivity
http://www.ncbi.nlm.nih.gov/pubmed/23183579

IL-13 Superkines

KIDNEY CANCER

Expression of IL-4 and IL-13 predicts recurrence and survival in localized clear-cell renal cell carcinoma
https://www.ncbi.nlm.nih.gov/pubmed/25973044

Phase I Trial of Intravenous IL-4 Pseudomonas Exotoxin Protein (NBI-3001) in Patients with Advanced Solid Tumors That Express the IL-4 Receptor
http://www.ncbi.nlm.nih.gov/pubmed/16000956

An improved circularly permuted interleukin 4-toxin is highly cytotoxic to human renal cell carcinoma cells
http://www.ncbi.nlm.nih.gov/pubmed/8660841

Human renal cell carcinoma cells are sensitive to the cytotoxic effect of a chimeric protein composed of human interleukin-4 and Pseudomonas exotoxin
http://www.ncbi.nlm.nih.gov/pubmed/8131209

LEUKEMIA AND LYMPHOMA

IL-4/CXCL12 loop is a key regulator of lymphoid stroma function in follicular lymphoma
https://www.ncbi.nlm.nih.gov/pubmed/28202459

Hodgkin lymphoma therapy with interleukin-4 receptor–directed cytotoxin in an infiltrating animal model
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1895022/

A recombinant IL-4-Pseudomonas exotoxin inhibits protein synthesis and overcomes apoptosis resistance in human CLL B cells
http://www.ncbi.nlm.nih.gov/pubmed/16038727

LUNG CANCER

IL-13 receptor α2 is a negative prognostic factor in human lung cancer and stimulates lung cancer growth in mice
https://www.ncbi.nlm.nih.gov/pubmed/26418721

Interleukin 4 receptor on human lung cancer: a molecular target for cytotoxin therapy
http://www.ncbi.nlm.nih.gov/pubmed/12429641

MDNA55 STRUCTURE, FUNCTION, MECHANISM

Overexpressed cell surface interleukin-4 receptor molecules can be successfully targeted for antitumor cytotoxin therapy
http://www.ncbi.nlm.nih.gov/pubmed/11642612

A chimeric protein comprised of IL-4 and Pseudomonas exotoxin is cytotoxic for activated human lymphocytes
http://www.ncbi.nlm.nih.gov/pubmed/8144944

A wide range of human cancers express interleukin 4 (IL4) receptors that can be targeted with chimeric toxin composed of IL4 and Pseudomonas exotoxin
http://www.ncbi.nlm.nih.gov/pubmed/8314773

Interleukin-4 receptors expressed on tumor cells may serve as a target for anticancer therapy using chimeric Pseudomonas exotoxin
http://www.ncbi.nlm.nih.gov/pubmed/8077061

Internalization property of interleukin-4 receptor alpha chain increases cytotoxic effect of interleukin-4 receptor-targeted cytotoxin in cancer cells
http://www.ncbi.nlm.nih.gov/pubmed/11801567

A circularly permuted recombinant interleukin 4 toxin with increased activity
http://www.ncbi.nlm.nih.gov/pubmed/8041715

Circularly permuted interleukin 4 retains proliferative and binding activity
http://www.ncbi.nlm.nih.gov/pubmed/8589260

Increased antitumor activity of a circularly permuted interleukin 4-toxin in mice with interleukin 4 receptor-bearing human carcinoma
http://www.ncbi.nlm.nih.gov/pubmed/7614471

Expression of high-affinity IL-4 receptors on human melanoma, ovarian and breast carcinoma cells
http://www.ncbi.nlm.nih.gov/pubmed/8287600

MESOTHELIOMA

New and emerging therapeutic options for malignant pleural mesothelioma: review of early clinical trials
https://www.ncbi.nlm.nih.gov/pubmed/25670913

Interleukin-4 receptor cytotoxin as therapy for human malignant pleural mesothelioma xenografts
http://www.ncbi.nlm.nih.gov/pubmed/15276492

Expression of interleukin-4 receptor alpha in human pleural mesothelioma is associated with poor survival and promotion of tumor inflammation
http://www.ncbi.nlm.nih.gov/pubmed/22261806

MULTIDRUG-RESISTANT TUMORS

Multidrug-resistant tumor cells remain sensitive to a recombinant interleukin-4-Pseudomonas exotoxin, except when overexpressing the multidrug resistance protein MRP1
http://www.ncbi.nlm.nih.gov/pubmed/14581376

OVARIAN CANCER

IL-13 regulates cancer invasion and metastasis through IL-13Rα2 via ERK/AP-1 pathway in mouse model of human ovarian cancer
https://www.ncbi.nlm.nih.gov/pubmed/21858811

Expression and targeting of interleukin-4 receptor for primary and advanced ovarian cancer therapy
http://www.ncbi.nlm.nih.gov/pubmed/16166317

PANCREATIC CANCER

The Presence of Interleukin-13 at Pancreatic ADM/PanIN Lesions Alters Macrophage Populations and Mediates Pancreatic Tumorigenesis
https://www.ncbi.nlm.nih.gov/pubmed/28514653

Endogenously Expressed IL-4Rα Promotes the Malignant Phenotype of Human Pancreatic Cancer In Vitro and In Vivo
https://www.ncbi.nlm.nih.gov/pubmed/28350325

Interleukin-4 cytotoxin therapy synergizes with gemcitabine in a mouse model of pancreatic ductal adenocarcinoma
http://www.ncbi.nlm.nih.gov/pubmed/17942922

Interleukin-4 enhances proliferation of human pancreatic cancer cells: evidence for autocrine and paracrine actions
http://www.ncbi.nlm.nih.gov/pubmed/15714203

Targeting interleukin-4 receptors for effective pancreatic cancer therapy
http://www.ncbi.nlm.nih.gov/pubmed/12097255

PROSTATE CANCER

Interleukin-4 induces a CD44high /CD49bhigh PC3 subpopulation with tumor-initiating characteristics
https://www.ncbi.nlm.nih.gov/pubmed/29236307

The immunosuppressive cytokine interleukin-4 increases the clonogenic potential of prostate stem-like cells by activation of STAT6 signaling
https://www.ncbi.nlm.nih.gov/pubmed/28553931

IL-4 / IL-13 mediated cell-to-cell fusion in prostate cancer progress
http://cancerres.aacrjournals.org/content/76/14_Supplement/925

Clinical investigation of the role of interleukin-4 and interleukin-13 in the evolution of prostate cancer
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3763424/

Interleukin-4 receptor-targeted cytotoxin therapy of androgen-dependent and -independent prostate carcinoma in xenograft models
http://www.ncbi.nlm.nih.gov/pubmed/12657719

RHABDOMYOSARCOMA

IL-4 receptor blockade abrogates satellite cell: rhabdomyosarcoma fusion and prevents tumor establishment
http://www.ncbi.nlm.nih.gov/pubmed/23897781

IL-4R drives dedifferentiation, mitogenesis, and metastasis in rhabdomyosarcoma
http://www.ncbi.nlm.nih.gov/pubmed/21536546

SARCOMAS

Constitutive Activation of Interleukin-13/STAT6 Contributes to Kaposi’s Sarcoma-Associated Herpesvirus-Related Primary Effusion Lymphoma Cell Proliferation and Survival
https://www.ncbi.nlm.nih.gov/pubmed/26246572

IL-4 receptor-directed cytotoxin for therapy of AIDS-associated KS tumors
http://www.ncbi.nlm.nih.gov/pubmed/12937611

Interleukin-4 receptor expression in vivo on human AIDS-related Kaposi’s sarcoma
http://www.ncbi.nlm.nih.gov/pubmed/9495455

Interleukin-4 receptor expression on AIDS-associated Kaposi’s sarcoma cells and their targeting by a chimeric protein comprised of circularly permuted interleukin-4 and Pseudomonas exotoxin
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2230073/

Interleukin-4 receptor-directed cytotoxin therapy of AIDS-associated Kaposi’s sarcoma tumors in xenograft model
http://www.ncbi.nlm.nih.gov/pubmed/10395328

THYROID CANCER

Autocrine production of interleukin-4 and interleukin-10 is required for survival and growth of thyroid cancer cells
https://www.ncbi.nlm.nih.gov/pubmed/16452205

Identification, characterization, and targeting of IL-4 receptor by IL-4-Pseudomonas exotoxin in mouse models of anaplastic thyroid cancer
http://www.ncbi.nlm.nih.gov/pubmed/26645899

Interleukin-4 stimulates papillary thyroid cancer cell survival: implications in patients with thyroid cancer and concomitant Graves’ disease
http://www.ncbi.nlm.nih.gov/pubmed/15181072

Thyroid cancer resistance to chemotherapeutic drugs via autocrine production of interleukin-4 and interleukin-10
http://www.ncbi.nlm.nih.gov/pubmed/14583474

TUMOR MICROENVIRONMENT

IL-4/CXCL12 loop is a key regulator of lymphoid stroma function in follicular lymphoma.
https://www.ncbi.nlm.ih.gov/pubmed/28202459

IL-4 blockade alters the tumor microenvironment and augments the response to cancer immunotherapy in a mouse model
https://www.ncbi.nlm.nih.gov/pubmed/28733709

IL4 Primes the Dynamics of Breast Cancer Progression via DUSP4 Inhibition
https://www.ncbi.nlm.nih.gov/pubmed/28400477

IL4 from T Follicular Helper Cells Downregulates Antitumor Immunity
https://www.ncbi.nlm.nih.gov/pubmed/27920023

IL-4 / IL-13 mediated cell-to-cell fusion in prostate cancer progress
http://cancerres.aacrjournals.org/content/76/14_Supplement/925

IL-4, a direct target of miR-340/429, is involved in radiation-induced aggressive tumor behavior in human carcinoma cells
https://www.ncbi.nlm.nih.gov/pubmed/27895317

IL-4 modulate the tumor microenvironment and response to cancer therapies
http://cancerres.aacrjournals.org/content/76/14_Supplement/1454.short

Targeting IL4/IL4R for the treatment of epithelial cancer metastasis
http://www.ncbi.nlm.nih.gov/pubmed/26385103

Partners in crime: VEGF and IL-4 conscript tumour-promoting macrophages
http://www.ncbi.nlm.nih.gov/pubmed/22367978

IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion
http://www.ncbi.nlm.nih.gov/pubmed/20080943

Human non-small cell lung cancer cells express a type 2 cytokine pattern
http://www.ncbi.nlm.nih.gov/pubmed/7641203

IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients
http://www.ncbi.nlm.nih.gov/pubmed/19414811

Aptamer-mediated blockade of IL4Rα triggers apoptosis of MDSCs and limits tumor progression
http://www.ncbi.nlm.nih.gov/pubmed/22282665

Alternative activation of tumor-associated macrophages by IL-4: priming for protumoral functions
http://www.ncbi.nlm.nih.gov/pubmed/21150330